Httk: R package for high-throughput toxicokinetics

Journal of Statistical Software

Volumn 79, Issue , 2017, Pages 1-26

  Pearce, Robert G ^a   Setzer, R Woodrow ^a   Strope, Cory L ^a   Sipes, Nisha S ^b   Wambaugh, John F ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

High throughput; Httk; Pharmacokinetics; ToxCast; Toxicokinetics

Indexed keywords

EID: 85015103855     PISSN: 15487660     EISSN: None     Source Type: Journal    
DOI: 10.18637/jss.v079.i04     Document Type: Article

References (58)

1. Aylward LL, Hays SM (2011). “Consideration of Dosimetry in Evaluation of ToxCastTM Data.” Journal of Applied Toxicology, 31(8), 741–751. doi:10.1002/jat.1626.
2. Birnbaum L, Brown R, Bischoff K, Foran J, Blancato J, Clewell H, Dedrick R (1994). “Physiological Parameter Values for PBPK Models.” Technical report, International Life Sciences Institute, Risk Science Institute, Washington.
3. Bois F, Maszle D (1997). “MCSim: A Monte Carlo Simulation Program.” Journal of Statistical Software, 2(1), 1–60. doi:10.18637/jss.v002.i09.
4. Bucher JR (2008). “Guest Editorial: NTP: New Initiatives, New Alignment.” Environmental Health Perspectives, 116(1), A14–A15. doi:10.1289/ehp.11100.
5. Campbell Jr JL, Clewell RA, Gentry PR, Andersen ME, Clewell III HJ (2012). “Physiologically Based Pharmacokinetic/Toxicokinetic Modeling.” In B Reisfeld, AN Mayeno (eds.), Computational Toxicology, volume 929 of Methods in Molecular Biology, pp. 439–499. Humana Press. doi:10.1007/978-1-62703-050-2_18.
6. Chiu WA, White P (2006). “Steady-State Solutions to PBPK Models and Their Applications to Risk Assessment I: Route-to-Route Extrapolation of Volatile Chemicals.” Risk Analysis, 26(3), 769–780. doi:10.1111/j.1539-6924.2006.00762.x.
7. Davies B, Morris T (1993). “Physiological Parameters in Laboratory Animals and Humans.” Pharmaceutical Research, 10(7), 1093–1095. doi:10.1023/a:1018943613122.
8. Egeghy PP, Vallero DA, Hubal EAC (2011). “Exposure-Based Prioritization of Chemicals for Risk Assessment.” Environmental Science & Policy, 14(8), 950–964. doi:10.1016/j.envsci.2011.07.010.
9. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB (2013). Bayesian Data Analysis. CRC Press.
10. Hilal SH, Karickhoff SW, Carreira LA (1995). “A Rigorous Test for SPARC’s Chemical Reactivity Models: Estimation of More Than 4300 Ionization pKas.” Quantitative Structure-Activity Relationships, 14(4), 348–355. doi:10.1002/qsar.19950140405.
11. Houston JB, Carlile DJ (1997). “Prediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices.” Drug Metabolism Reviews, 29(4), 891–922. doi:10.3109/03602539709002237.
12. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, others (2003). “The Systems Biology Markup Language (SBML): A Medium for Representation and Exchange of Biochemical Network Models.” Bioinformatics, 19(4), 524–531.
13. Ito K, Houston JB (2004). “Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes.” Pharmaceutical Research, 21(5), 785–792. doi:10.1023/b:pham.0000026429.12114.7d.
14. ® Population-Based ADME Simulator.” Expert Opinion on Drug Metabolism & Toxicology, 5(2), 211–223. doi:10.1517/17425250802691074.
15. Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK (2014). “National Health and Nutrition Examination Survey: Sample Design, 2011–2014.” Vital and Health Statistics – Series 2, Data Evaluation and Methods Research, 162, 1–33.
16. Jones OA, Voulvoulis N, Lester JN (2002). “Aquatic Environmental Assessment of the Top 25 English Prescription Pharmaceuticals.” Water Research, 36(20), 5013–5022. doi:10.1016/s0043-1354(02)00227-0.
17. Judson R, Richard A, Dix DJ, Houck K, Martin M, Kavlock R, Dellarco V, Henry T, Holderman T, Sayre P, Tan S, Carpenter T, Smith E (2008). “The Toxicity Data Landscape for Environmental Chemicals.” Environmental Health Perspectives, 117(5), 685–695. doi: 10.1289/ehp.0800168.
18. Judson RS, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, Mortensen HM, Reif DM, Rotroff DM, Shah I, Richard AM, Dix DJ (2010). “In Vitro Screening of Environmental Chemicals for Targeted Testing Prioritization: The ToxCast Project.” Environmental Health Perspectives, 118(4), 485–492. doi:10.1289/ehp.0901392.
19. Kilford PJ, Gertz M, Houston, Brian J, Galetin A (2008). “Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data.” Drug Metabolism and Disposition, 36(7), 1194–1197. doi: 10.1124/dmd.108.020834.
20. Naritomi Y, Terashita S, Kagayama A, Sugiyama Y (2003). “Utility of Hepatocytes in Predicting Drug Metabolism: Comparison of Hepatic Intrinsic Clearance in Rats and Humans in Vivo and in Vitro.” Drug Metabolism and Disposition, 31(5), 580–588. doi: 10.1124/dmd.31.5.580.
21. Obach RS (1999). “Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of in Vitro Half-Life Approach and Nonspecific Binding to Microsomes.” Drug Metabolism and Disposition, 27(11), 1350–1359.
22. Obach RS, Lombardo F, Waters NJ (2008). “Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds.” Drug Metabolism and Disposition, 36(7), 1385–405. doi:10.1124/dmd.108.020479.
23. O’Flaherty EJ (1981). Toxicants and Drugs: Kinetics and Dynamics. John Wiley & Sons, New York.
24. Park YH, Lee K, Soltow QA, Strobel FH, Brigham KL, Parker RE, Wilson ME, Sutliff RL, Mansfield KG, Wachtman LM, Ziegler TR, Jones DP (2012). “High-Performance Metabolic Profiling of Plasma from Seven Mammalian Species for Simultaneous Environmental Chemical Surveillance and Bioeffect Monitoring.” Toxicology, 295(1–3), 47–55. doi:10.1016/j.tox.2012.02.007.
25. Pelekis D, Krewski K, Krishnan M (1997). “Physiologically Based Algebraic for Predicting Steady-State Toxicokinetics of Inhaled Vapors.” Toxicology Mechanisms and Methods, 7(3), 205–226. doi:10.1080/105172397243169.
26. Poulin P, Haddad S (2012). “Advancing Prediction of Tissue Distribution and Volume of Distribution of Highly Lipophilic Compounds from a Simplified Tissue-Composition-Based Model as a Mechanistic Animal Alternative Method.” Journal of Pharmaceutical Sciences, 101(6), 2250–2261. doi:10.1002/jps.23090.
27. Riley RJ, McGinnity DF, Austin RP (2005). “A Unified Model for Predicting Human Hepatic, Metabolic Clearance from in Vitro Intrinsic Clearance Data in Hepatocytes and Microsomes.” Drug Metabolism and Disposition, 33(9), 1304–11. doi:10.1124/dmd.105.004259.
28. Ring CL, Pearce RG, Setzer RW, Wetmore BA, Wambaugh JF (2017). “Identifying Populations Sensitive to Environmental Chemicals by Simulating Toxicokinetic Variability.” Environment International, 106, 105–118. doi:10.1016/j.envint.2017.06.004.
29. Rotroff DM, Wetmore BA, Dix DJ, Ferguson SS, Clewell HJ, Houck KA, Lecluyse EL, Andersen ME, Judson RS, Smith CM, Sochaski MA, Kavlock RJ, Boellmann F, Martin MT, Reif DM, Wambaugh JF, Thomas RS (2010). “Incorporating Human Dosimetry and Exposure into High-Throughput in Vitro Toxicity Screening.” Toxicological Sciences, 117(2), 348–358. doi:10.1093/toxsci/kfq220.
30. Rovida C, Hartung T (2009). “Re-Evaluation of Animal Numbers and Costs for in Vivo Tests to Accomplish REACH Legislation Requirements for Chemicals – a Report by the Transatlantic Think Tank for Toxicology (t4).” Altex, 26(3), 187–208. doi:10.14573/altex.2009.3.187.
31. Rowland M, Balant L, Peck C (2004). “Physiologically Based Pharmacokinetics in Drug Development and Regulatory Science: A Workshop Report (Georgetown University, Washington, DC, May 29–30, 2002).” AAPS PharmSci, 6(1), 56–67. doi:10.1208/ps060106.
32. Ruark CD, Hack CE, Robinson PJ, Mahle DA, Gearhart JM (2014). “Predicting Passive and Active Tissue:Plasma Partition Coefficients: Interindividual and Interspecies Variability.” Journal of Pharmaceutical Sciences, 103(7), 2189–2198. doi:10.1002/jps.24011.
33. Sauro HM, Fell D (2000). “Jarnac: A System for Interactive Metabolic Analysis.” In Animating the Cellular Map: Proceedings of the 9th International Meeting on BioThermoKinetics, pp. 221–228. Stellenbosch University Press.
34. Schmitt W (2008a). “Corrigendum to “General Approach for the Calculation of Tissue to Plasma Partition Coefficients” [Toxicology in Vitro 22 (2008) 457–467].” Toxicology in Vitro, 22(6), 1666. doi:10.1016/j.tiv.2008.04.020.
35. Schmitt W (2008b). “General Approach for the Calculation of Tissue to Plasma Partition Coefficients.” Toxicology in Vitro, 22(2), 457–467. doi:10.1016/j.tiv.2007.09.010.
36. Setzer RW (2001). “The odesolve Package: Solvers for Ordinary Differential Equations.” R package version 0.1-1. URL https://CRAN.R-project.org/src/contrib/Archive/odesolve/.
37. Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of Hepatic Clearance and Availability by Cryopreserved Human Hepatocytes: An Application of Serum Incubation Method.” Drug Metabolism and Disposition, 30(8), 892–896. doi:10.1124/dmd.30.8.892.
38. Snyder WS, Cook M, Nasset E, Karhausen L, Howells G, Tipton I (1975). “Report of the Task Group on Reference Man.” ICRP Publication 23, International Commission on Radiological Protection, Elmsford.
39. Soetaert K, Petzoldt T, Setzer RW (2010). “Solving Differential Equations in R: Package deSolve.” Journal of Statistical Software, 33(9), 1–25. doi:10.18637/jss.v033.i09.
40. Soetaert K, Petzoldt T, Setzer RW (2016). deSolve: Solvers for Initial Value Problems of Differential Equations (ODE, DAE, DDE). R package version 1.14, URL https://CRAN.R-project.org/package=deSolve.
41. Tan YM, Liao KH, Clewell III HJ (2006). “Reverse Dosimetry: Interpreting Trihalomethanes Biomonitoring Data Using Physiologically Based Pharmacokinetic Modeling.” Journal of Exposure Science & Environmental Epidemiology, 17(7), 591–603. doi:10.1038/sj.jes.7500540.
42. Thomas RS, Lytle WE, Keefe TJ, Constan AA, Yang RSH (1996). “Incorporating Monte Carlo Simulation into Physiologically Based Pharmacokinetic Models Using Advanced Continuous Simulation Language (ACSL): A Computational Method.” Toxicological Sciences, 31(1), 19–28.
43. Thomas RS, Philbert MA, Auerbach SS, Wetmore BA, Devito MJ, Cote I, Rowlands JC, Whelan MP, Hays SM, Andersen ME, others (2013). “Incorporating New Technologies into Toxicity Testing and Risk Assessment: Moving from 21st Century Vision to a Data-Driven Framework.” Toxicological Sciences, 136(1), 4–18. doi:10.1093/toxsci/kft178.
44. Tonnelier A, Coecke S, Zaldivar JM (2012). “Screening of Chemicals for Human Bioaccumulative Potential with a Physiologically Based Toxicokinetic Model.” Archives of Toxicology, 86(3), 393–403. doi:10.1007/s00204-011-0768-0.
45. Wambaugh J, Pearce R, Ring C, Davis J, Sipes N, Setzer RW (2017). httk: High-Throughput Toxicokinetics. R package version 1.7, URL https://CRAN.R-project.org/package=httk.
46. Wambaugh JF, Setzer RW, Pitruzzello AM, Liu J, Reif DM, Kleinstreuer NC, Wang NCY, Sipes N, Martin M, Das K, others (2013a). “Dosimetric Anchoring of In Vivo and In Vitro Studies for Perfluorooctanoate and Perfluorooctanesulfonate.” Toxicological Sciences, 136(2), 308–327.
47. Wambaugh JF, Setzer RW, Reif DM, Gangwal S, Mitchell-Blackwood J, Arnot JA, Joliet O, Frame A, Rabinowitz J, Knudsen TB, others (2013b). “High-Throughput Models for Exposure-Based Chemical Prioritization in the ExpoCast Project.” Environmental Science & Technology, 47(15), 8479–8488. doi:10.1021/es400482g.
48. Wambaugh JF, Wang A, Dionisio KL, Frame A, Egeghy P, Judson R, Setzer RW (2014). “High Throughput Heuristics for Prioritizing Human Exposure to Environmental Chemicals.” Environmental Science & Technology, 48(21), 12760–12767. doi:10.1021/es503583j.
49. Wambaugh JF, Wetmore BA, Pearce R, Strope C, Goldsmith R, Sluka JP, Sedykh A, Tropsha A, Bosgra S, Shah I, others (2015). “Toxicokinetic Triage for Environmental Chemicals.” Toxicological Sciences, 147(1), 55–67. doi:10.1093/toxsci/kfv118.
50. Waters NJ, Jones R, Williams G, Sohal B (2008). “Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein Binding.” Journal of Pharmaceutical Sciences, 97(10), 4586–4595. doi:10.1002/jps.21317.
51. Wetmore BA (2015). “Quantitative in Vitro-to-in Vivo Extrapolation in a High-Throughput Environment.” Toxicology, 332, 94–101. doi:10.1016/j.tox.2014.05.012.
52. Wetmore BA, Wambaugh JF, Ferguson SS, Li L, Clewell HJ, Judson RS, Freeman K, Bao W, Sochaski MA, Chu TM, Black MB, Healy E, Allen B, Andersen ME, Wolfinger RD, Thomas RS (2013). “Relative Impact of Incorporating Pharmacokinetics on Predicting In Vivo Hazard and Mode of Action from High-Throughput In Vitro Toxicity Assays.” Toxicological Sciences, 132(2), 327–346. doi:10.1093/toxsci/kft012.
53. Wetmore BA, Wambaugh JF, Ferguson SS, Sochaski MA, Rotroff DM, Freeman K, Clewell III HJ, Dix DJ, Andersen ME, Houck KA, Allen B, Judson RS, Singh R, Kavlock RJ, Richard AM, Thomas RS (2012). “Integration of Dosimetry, Exposure, and High-Throughput Screening Data in Chemical Toxicity Assessment.” Toxicological Sciences, 125(1), 157–174. doi:10.1093/toxsci/kfr254.
54. Wickham H (2009). ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag, New York.
55. Wilkinson GR, Shand DG (1975). “Commentary: A Physiological Approach to Hepatic Drug Clearance.” Clinical Pharmacology & Therpeutics, 18(4), 377–390. doi:10.1002/cpt1975184377.
56. Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT (2007). “Misuse of the Well-Stirred Model of Hepatic Drug Clearance.” Drug Metabolism and Disposition, 35(3), 501–502. doi:10.1124/dmd.106.013359.
57. Yang RSH, Lu Y (2007). “The Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Risk Assessment.” In MG Robson, WA Toscano (eds.), Risk Assessment for Environmental Health, pp. 85–120. John Wiley & Sons.
58. Yun YE, Cotton CA, Edginton AN (2014). “Development of a Decision Tree to Classify the Most Accurate Tissue-Specific Tissue to Plasma Partition Coefficient Algorithm for a Given Compound.” Journal of Pharmacokinetics and Pharmacodynamics, 41(1), 1–14. doi:10.1007/s10928-013-9342-0.